Leerink Partnrs Issues Negative Estimate for Sanofi Earnings

Key Points

• Leerink Partnrs has reduced their FY2025 EPS estimate for Sanofi from $4.53 to $4.35, aligning closely with the consensus estimate of $4.36.
• Sanofi's stock increased by 2.4% to $46.75, despite reporting a quarterly EPS of $0.90 which missed expectations of $0.96.
• Several firms have provided ratings for Sanofi, with BNP Paribas setting a price target of $65.00 and a majority of analysts giving the stock a "Buy" or "Strong Buy" rating.

Sanofi (NASDAQ:SNY - Free Report) - Equities researchers at Leerink Partnrs reduced their FY2025 EPS estimates for Sanofi in a research report issued on Thursday, July 31st. Leerink Partnrs analyst D. Risinger now forecasts that the company will earn $4.35 per share for the year, down from their previous forecast of $4.53. The consensus estimate for Sanofi's current full-year earnings is $4.36 per share. Leerink Partnrs also issued estimates for Sanofi's FY2026 earnings at $4.62 EPS, FY2027 earnings at $4.65 EPS, FY2028 earnings at $5.03 EPS and FY2029 earnings at $5.53 EPS.

A number of other research firms have also issued reports on SNY. BNP Paribas began coverage on shares of Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target on the stock. Wall Street Zen upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a report on Saturday. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Morgan Stanley set a $56.00 price target on shares of Sanofi in a report on Monday, June 2nd. Finally, Barclays restated an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $62.00.

Sanofi Stock Up 2.4%

SNY stock opened at $46.75 on Monday. Sanofi has a 12 month low of $44.73 and a 12 month high of $60.12. The firm has a market cap of $114.80 billion, a PE ratio of 11.24, a P/E/G ratio of 1.12 and a beta of 0.48. The firm has a 50 day simple moving average of $49.10 and a 200 day simple moving average of $52.11. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. During the same period in the prior year, the company earned $1.73 earnings per share. The firm's revenue for the quarter was down 7.0% on a year-over-year basis.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Invesco Ltd. increased its stake in Sanofi by 3.5% in the 4th quarter. Invesco Ltd. now owns 12,059,283 shares of the company's stock valued at $581,619,000 after buying an additional 408,752 shares during the period. Bank of America Corp DE increased its stake in Sanofi by 3.8% in the 4th quarter. Bank of America Corp DE now owns 12,017,140 shares of the company's stock valued at $579,587,000 after buying an additional 441,637 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Sanofi by 1.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 11,036,878 shares of the company's stock valued at $612,106,000 after buying an additional 193,196 shares during the period. Federated Hermes Inc. increased its stake in Sanofi by 58.5% in the 1st quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company's stock valued at $218,933,000 after buying an additional 1,456,269 shares during the period. Finally, Nuveen Asset Management LLC increased its stake in shares of Sanofi by 1.0% during the 4th quarter. Nuveen Asset Management LLC now owns 3,676,224 shares of the company's stock worth $177,304,000 after purchasing an additional 34,660 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.